Innovus Pharma Receives Product License Approval Of Ejectdelay™ For Premature Ejaculation From Health Canada
Published: Dec 06, 2013
LA JOLLA, Calif., Dec. 6, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that the Company received the approval of its product license for its over the counter ("OTC") benzocaine-based topical premature ejaculation treatment EjectDelay™ in Canada.
Help employers find you! Check out all the jobs and post your resume.